Objective. The purpose of this study was to prospectively follow a group of
women with breast cancer, on tamoxifen, for the development of endometrial
pathologies.
Materials and methods. Eighty women with breast cancer, on tamoxifen, were
prospectively followed every 6 months with pelvic examination, Pap smear, v
aginal ultrasound, and endometrial biopsy.
Results. Nine women were lost to follow-up prior to initiation of treatment
and 4 refused biopsies, leaving 67 patients for evaluation. Fifty (74.6%)
of the 67 patients were already on tamoxifen for a mean duration of 15.8 +/
- 16.6 months and had a baseline benign, unremarkable endometrium at the ti
me of entry into the study. The total duration of treatment was 32.5 +/- 19
.6 months (median 30 months). The mean age of the patients was 51.7 +/- 9.9
years (median 52 years). Of the patients, 56.7% were postmenopausal. Sixty
-three patients had a benign endometrium (mean age 51.8 +/- 10.1 years, mea
n duration 33.1 +/- 19.6 months). Two patients had simple hyperplasia (mean
age 43.5 years, duration 28.5 +/- 33.2 months), 1 patient had complex hype
rplasia with atypia (age 57 years, duration 13 months), and another patient
developed adenocarcinoma (grade 3) after 22 months. These 4 patients had a
bnormal vaginal bleeding. Seven patients developed endometrial polyps (mean
age 54.0 +/- 8.5 years, duration 36 +/- 24.2 months). The mean endometrial
thickness for patients with histologically unremarkable and abnormal endom
etrium was not significantly different (7.6 +/- 3.9 vs 8.8 +/- 5.0 mm, resp
ectively) (median 7.0 mm for both groups). No endometrial thickness cutoff
point reached statistical significance. The patient who developed endometri
al cancer had a thickness of only 3 mm.
Conclusion. All patients who developed an abnormal endometrium had abnormal
vaginal bleeding. There was no correlation between endometrial thickness a
nd endometrial pathology; thus the value of routine screening remains contr
oversial. (C) 1999 Academic Press.